Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Ordinary shares, par value 0.002 GBP per share
-
Shares outstanding
-
147,336,360
-
Total 13F shares
-
72,578,425
-
Share change
-
+2,238,092
-
Total reported value
-
$469,582,127
-
Put/Call ratio
-
8.2%
-
Price per share
-
$6.47
-
Number of holders
-
47
-
Value change
-
+$14,480,757
-
Number of buys
-
21
-
Number of sells
-
11
Institutional Holders of Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) as of Q3 2023
As of 30 Sep 2023,
Centessa Pharmaceuticals plc - Ordinary shares, par value 0.002 GBP per share (CNTA) was held by
47 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
72,578,425 shares.
The largest 10 holders included
Medicxi Ventures Management (Jersey) Ltd, GENERAL ATLANTIC, L.P., BVF INC/IL, EcoR1 Capital, LLC, Vida Ventures Advisors, LLC, OUP Management Co., LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., FMR LLC, PRICE T ROWE ASSOCIATES INC /MD/, and TCG Crossover Management, LLC.
This page lists
46
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.